Trump Signs Executive Order Advancing Psychedelic-Assisted Treatments

President Trump signed an executive order on April 20, 2026 directing federal agencies to accelerate research and regulatory pathways for psychedelic-assisted therapies, including psilocybin and MDMA. Advocates praised the order as a landmark step toward legitimizing treatments for PTSD, depression, and addiction, with veterans' groups particularly supportive given the unmet need among combat veterans. However, medical researchers and bioethicists expressed concern that the order could politicize the scientific review process, potentially fast-tracking approvals ahead of rigorous clinical evidence. The FDA had previously rejected MDMA-assisted therapy in 2024, citing data integrity concerns. The EO instructs the Department of Health and Human Services and the FDA to develop expedited review protocols, and directs the VA to pilot psychedelic treatment programs. Critics warned that executive pressure on the FDA's independent review process sets a dangerous precedent for drug approvals.